Quick Answer
Indaptus Therapeutics, Inc. reported Net Income of -$20.85 million for fiscal year 2025.
Indaptus Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$20.85M -38.8% |
-$15.02M +2.6% |
-$15.42M -7.7% |
-$14.32M -85.7% |
-$7.71M -115.2% |
-$3.58M |
| Diluted EPS | -$21.58 +52.0% |
-$44.96 -2356.8% |
-$1.83 -5.8% |
-$1.73 | — | — |
| Total Assets | $9.31M +26.9% |
$7.34M -50.8% |
$14.92M -46.8% |
$28.06M -30.8% |
$40.58M +2182.4% |
$1.78M |
| Cash and Equivalents | $8.51M +47.0% |
$5.79M -56.7% |
$13.36M +38.8% |
$9.63M -75.4% |
$39.13M +2289.8% |
$1.64M |
| Stockholders Equity | $3.15M -20.1% |
$3.94M -67.3% |
$12.08M -51.0% |
$24.63M -31.4% |
$35.90M +15202.8% |
-$237.7K -107.4% |
| R&D Expense | $9.34M +28.8% |
$7.25M -4.9% |
$7.62M +20.5% |
$6.32M +150.7% |
$2.52M -5.0% |
$2.66M |
| Operating Income | -$19.83M -29.1% |
-$15.37M +6.2% |
-$16.38M -9.8% |
-$14.91M -92.9% |
-$7.73M -114.7% |
-$3.60M |
| Shares Outstanding | 604,963 +41.1% |
428,799 -94.9% |
8.40M +0.0% |
8.40M +1.7% |
8.26M +324.7% |
1.94M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$2.98M | +3.1% | +43.1% |
| Diluted EPS | September 30, 2025 | -$2.98 | +67.0% | +67.2% |
| Total Assets | September 30, 2025 | $6.84M | -17.0% | +0.0% |
| Cash and Equivalents | September 30, 2025 | $5.83M | -21.1% | -5.4% |
| Stockholders Equity | September 30, 2025 | $4.61M | -23.3% | +375.2% |
| R&D Expense | September 30, 2025 | $1.52M | +3.5% | -30.0% |
| Operating Income | September 30, 2025 | -$2.65M | +15.7% | +40.6% |
| Shares Outstanding | September 30, 2025 | 1.64M | -83.9% | +171.4% |
- Indaptus Therapeutics, Inc. reported Net Income of -$20.85 million for fiscal year 2025.
- Indaptus Therapeutics, Inc. showed a decrease of -38.8% in Net Income compared to the prior fiscal year.
- Indaptus Therapeutics, Inc. reported Diluted EPS of $21.58 per share (loss) for fiscal year 2025.
- Indaptus Therapeutics, Inc. showed an increase of +52.0% in Diluted EPS compared to the prior fiscal year.
- Indaptus Therapeutics, Inc. reported Total Assets of $9.31 million for fiscal year 2025.
- Indaptus Therapeutics, Inc. showed an increase of +26.9% in Total Assets compared to the prior fiscal year.
- Indaptus Therapeutics, Inc. reported Cash and Equivalents of $8.51 million for fiscal year 2025.
- Indaptus Therapeutics, Inc. showed an increase of +47.0% in Cash and Equivalents compared to the prior fiscal year.
- Indaptus Therapeutics, Inc. reported Stockholders Equity of $3.15 million for fiscal year 2025.
- Indaptus Therapeutics, Inc. showed a decrease of -20.1% in Stockholders Equity compared to the prior fiscal year.
- Indaptus Therapeutics, Inc. reported R&D Expense of $9.34 million for fiscal year 2025.
- Indaptus Therapeutics, Inc. showed an increase of +28.8% in R&D Expense compared to the prior fiscal year.
- Indaptus Therapeutics, Inc. reported Operating Income of -$19.83 million for fiscal year 2025.
- Indaptus Therapeutics, Inc. showed a decrease of -29.1% in Operating Income compared to the prior fiscal year.
- Indaptus Therapeutics, Inc. reported Shares Outstanding of 2.17 million shares for fiscal year 2025.
- Indaptus Therapeutics, Inc. showed an increase of +258.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: